Vermillion To Present at 27th Annual ROTH Conference on March 9

AUSTIN, Texas, March 3, 2015 /PRNewswire/ -- Vermillion, Inc. VRML, a bio-analytical solutions company focused on gynecologic disease, today announced management will present at the 27^th Annual ROTH Conference, which is being held at the Ritz-Carlton in Dana Point, California from March 8 to March 11.

President and CEO of Vermillion, Valerie Palmieri, will be presenting on Monday, March 9 at 12:00 noon PST. She will be joined by Eric Schoen, the company's Vice President of Finance and Chief Accounting Officer. For more information about the conference or to schedule a one-on-one meeting with Vermillion management, please contact your ROTH representative or email conference@roth.com.

About Vermillion
Vermillion, Inc. VRML is dedicated to the discovery, development and commercialization of novel high-value diagnostic and bio-analytical solutions that help physicians diagnose, treat and improve outcomes for women. Vermillion, along with its prestigious scientific collaborators, are actively developing care pathways for improved management of gynecologic disease.

The company's lead diagnostic, OVA1®, is a blood test for pre-surgical assessment of ovarian tumors for malignancy, using an innovative algorithmic approach coupled with diagnostics.  As the first FDA-cleared, protein-based In Vitro Diagnostic Multivariate Index Assay, OVA1 represents a new class of software-based diagnostics. For additional information, including published clinical trials, visit www.vermillion.com.

Investor Relations Contact:
Michael Wood
LifeSci Advisors LLC
Tel 1-646-597-6983
mwood@lifesciadvisors.com

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/vermillion-to-present-at-27th-annual-roth-conference-on-march-9-300044859.html

SOURCE Vermillion, Inc.